ProMIS Neurosciences Q2 2024: Positive Phase 1a data for PMN310; secures up to $122.7M PIPE

ProMIS Neurosciences Inc.

2024-Q2 EPS reported -$0.32

Phase 1a of PMN310 in Alzheimer's showed no SAEs; CSF levels >100x oligomer concentration, half-life ~25 days supporting monthly dosing.
PIPE financing closed July 2024 with initial $30.3M; up to $122.7M total tied to warrant milestones from healthcare specialist investors.
Cash and equivalents $1.0M at June 30, 2024 (down from $12.6M at Dec 31, 2023); subsequent PIPE strengthens balance sheet.
Net loss $2.6M for Q2 2024 vs $2.3M in Q2 2023; R&D expenses $1.6M (up $0.6M YoY) driven by PMN310 clinical costs.
Company expects to report topline results from all five cohorts in H2 2024 and initiate a Phase 1b trial in 100 AD patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.